Seres Therapeutics, Inc. (MCRB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated February 27, 2026, discloses significant changes to the executive leadership of Seres Therapeutics, Inc. The reported events are effective as of March 2, 2026. The filing details the appointment of new officers and the departure of the previous Co-CEOs.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
The primary material change is the restructuring of the Company's executive leadership:
- Departure: Thomas J. DesRosier and Marella Thorell ceased serving as Co-Presidents and Co-Chief Executive Officers.
- Appointments:
- Richard N. Kender: Appointed Executive Chair of the Board and Interim Chief Executive Officer.
- Matthew Henn, Ph.D.: Appointed President (in addition to his role as Chief Scientific Officer).
- Kelly Brady, M.S.: Appointed Executive Vice President, Chief Operating Officer (previously Senior Vice President, Clinical Development).
- Continued Roles: Mr. DesRosier remains Executive Vice President, Chief Legal Officer, and Ms. Thorell remains Executive Vice President, Chief Financial Officer.
Compensation Arrangements and Outlook
New and amended employment agreements were executed effective March 2, 2026, with the following key terms:
- Richard N. Kender (Interim CEO):
- Base Salary: $520,000 annually.
- Target Bonus: 55% of base salary.
- Signing Bonus: $250,000 (subject to repayment if terminated for cause or resignation without good reason before Dec 31, 2026).
- Equity: Options to purchase 200,000 shares vesting over 36 months. 25% of these options are contingent on stockholder approval of a plan amendment.
- Matthew Henn, Ph.D. (President):
- Base Salary: Increased to $505,000 annually.
- Target Bonus: Increased to 45% of base salary.
- Retention Bonus: $230,000 (subject to repayment conditions similar to Mr. Kender).
- Equity: Options to purchase 100,000 shares with a 25% cliff vesting on the first anniversary, followed by quarterly vesting. 25% contingent on plan amendment approval.
- Kelly Brady, M.S. (EVP, COO):
- Base Salary: Increased to $475,000 annually.
- Target Bonus: Increased to 45% of base salary.
- Retention Bonus: $230,000 (subject to repayment conditions).
- Severance: Enhanced to 1.0x salary + bonus for change in control terminations and 12 months of base salary for other qualifying terminations.
- Equity: Options to purchase 75,000 shares with vesting terms similar to Dr. Henn. 25% contingent on plan amendment approval.
Risks and Contingencies: The filing includes standard forward-looking statements regarding the executive transitions. A specific contingency exists for the equity grants: 25% of the options granted to all three executives will be forfeited if the proposed amendment to the 2025 Incentive Award Plan is not approved by stockholders at the 2026 annual meeting.
Investor Verification Checklist
- Verify the outcome of the stockholder vote on the 2025 Incentive Award Plan amendment at the 2026 annual meeting, as this determines the vesting of 25% of the new equity grants.
- Review the Company's most recent Form 10-Q (filed November 5, 2025) for updated risk factors and financial liquidity status, as this 8-K does not provide current financial metrics.
- Monitor the transition period to ensure the new leadership structure stabilizes operations and clinical development timelines.
- Confirm the exact exercise price of the new stock options once the fair market value is determined on the grant date (second business day after filing).